Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

BACKGROUND AND OBJECTIVES: Entospletinib is a selective, reversible, adenosine triphosphate-competitive small-molecule spleen tyrosine kinase (SYK) inhibitor that blocks B cell receptor-mediated signaling and proliferation in B lymphocytes. This study evaluated the safety, pharmacokinetics, and phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramanathan, Srini, Di Paolo, Julie A., Jin, Feng, Shao, Lixin, Sharma, Shringi, Robeson, Michelle, Kearney, Brian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250654/
https://www.ncbi.nlm.nih.gov/pubmed/27785737
http://dx.doi.org/10.1007/s40261-016-0476-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250654/
https://www.ncbi.nlm.nih.gov/pubmed/27785737
http://dx.doi.org/10.1007/s40261-016-0476-x

Ejemplares similares